{"nctId":"NCT01011413","briefTitle":"Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.","startDateStruct":{"date":"2011-08"},"conditions":["HIV Infections"],"count":636,"armGroups":[{"label":"600 milligram (mg) Efavirenz","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Efavirenz 600mg"]},{"label":"400mg Efavirenz","type":"EXPERIMENTAL","interventionNames":["Drug: Efavirenz 400mg"]}],"interventions":[{"name":"Efavirenz 600mg","otherNames":["Matrix EFV 200mg tablets"]},{"name":"Efavirenz 400mg","otherNames":["Matrix EFV 200mg tablets","Matrix EFV 200mg matched placebo tablets."]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HIV-1 positive by licensed diagnostic test\n* aged \\>16 years of age (or minimum age as determined by local regulations or as legal requirements dictate)\n* 50 \\< cluster of differentiation (CD)4 \\<500 cells/µL\n* No prior AIDS-defining illness, using the Center for Diseases Control 1993 Case Definition (except pulmonary tuberculosis)\n* HIV RNA ≥1000 copies/mL\n* no prior exposure to antiretroviral therapy (ART) (including short course ART for preventing MTCT)\n* calculated creatinine clearance (CLCr) more than or equal to 50 mL/min (Cockcroft-Gault formula)\n* provision of written informed consent.\n\nExclusion Criteria:\n\n* the following laboratory values:\n\n  * absolute neutrophil count (ANC) \\<500 cells/μL\n  * hemoglobin \\<7.0 g/dL\n  * platelet count \\<50,000 cells/μL\n  * alanine aminotransferase and/or aspartate aminotransferase \\>5 x upper limit of normal\n* pregnant women or nursing mothers\n* active opportunistic or malignant disease not under adequate control\n* use of immunomodulators within 30 days prior to screening\n* use of any prohibited medications\n* current alcohol or illicit substance use that might adversely affect study participation","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Plasma HIV-1 RNA <200 Copies/mL 48 Weeks After Randomisation","description":"Percentage of participants in each of the treatment arms with centrally quantified plasma HIV-1 RNA viral load \\<200 copies/mL 48 weeks after randomisation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null},{"groupId":"OG001","value":"94.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Plasma HIV-1 RNA <400 Copies/mL and <50 Copies/mL at 48 and 96 Weeks After Randomisation","description":"Percentage of participants in each of the two treatment arms with plasma HIV-1 RNA \\<400 copies/mL and \\<50 copies/mL at 48 and 96 weeks after randomisation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"268","spread":null},{"groupId":"OG001","value":"277","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"280","spread":null},{"groupId":"OG001","value":"291","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in CD4+ T-cell Count","description":"Mean change from baseline to week 96 in CD4+ T-cell count/mm3 between the two treatment arms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"209","spread":null},{"groupId":"OG001","value":"235","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Endpoints: Opportunistic Disease or Death, and Serious Non-AIDS-defining Events and Non-AIDS-related Mortality","description":"Number of participants in each randomised arm diagnosed with a serious non-AIDS defining event, who die from an AIDS-defining event, who die from a non-AIDS-defining event","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"14","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"292","spread":null},{"groupId":"OG001","value":"301","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Metabolic Endpoints","description":"Change from baseline to week 96 in fasted total cholesterol, high density cholesterol and low density cholesterol, and glucose between randomised treatment arms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.62","spread":null},{"groupId":"OG001","value":"0.54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":null},{"groupId":"OG001","value":"0.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":null},{"groupId":"OG001","value":"0.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":null},{"groupId":"OG001","value":"0.40","spread":null}]}]}]},{"type":"SECONDARY","title":"Adherence: Median Scores of Self-reported Adherence to Randomised Study Medications","description":"AIDS Clinical Trials Group (ACTG) 7-day adherence questionnaire scores. Maximum value is all pills taken every day; minimum value is no pills taken per day. Higher scores indicate a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"256","spread":null},{"groupId":"OG001","value":"271","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasted Insulin Levels","description":"Change from baseline to week 96 in fasted insulin levels","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Selected Serum Biochemical Parameters","description":"Change from baseline to week 96 in alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase levels between randomised treatment arms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.53","spread":null},{"groupId":"OG001","value":"0.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.71","spread":null},{"groupId":"OG001","value":"-1.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.75","spread":null},{"groupId":"OG001","value":"21.23","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Estimate Creatinine Clearance","description":"Change from baseline to week 96 in estimate creatinine clearance between randomised treatment arms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":null},{"groupId":"OG001","value":"1.59","spread":null}]}]}]},{"type":"SECONDARY","title":"Steady-state Efavirenz Concentrations","description":"Steady-state efavirenz mid-dosing interval plasma concentrations","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.85","spread":null},{"groupId":"OG001","value":"2.10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":309},"commonTop":["dizziness","rash","upper respiratory tract infection","diarrhoea","headache"]}}}